凯莫德

Chemed Corp earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 18% premium over our quantitative fair value estimate of $433.21 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's valuation metrics undermine our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 12.5% falls in the bottom 20% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

The firm's balance sheet is an additional cause for concern. Low leverage can limit a company's ability to invest in growth, potentially reducing shareholder value compared with a balanced use of debt and equity financing. The firm's debt to EBITDA ratio of 0.4, a core component of leverage, lies in the bottom 20% globally. With little debt relative to assets, this firm has a "lazy" balance sheet, which can depress returns on invested capital. This characteristic further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.